论文部分内容阅读
目的探讨晚期可切除直肠癌手术后进行同步放化疗的疗效。方法 80例晚期直肠癌患者根据治疗方法分为治疗组和对照组,每组40例。所有患者均行全直肠系膜切除术治疗,术后治疗组患者给予同步放化疗。结果两组患者术后切口感染、吻合口漏、肠梗阻等并发症发生率比较差异无统计学意义(P>0.05)。两组患者不良反应主要为乏力、恶心呕吐、腹泻和血小板减少等,组间差异无统计学意义(P>0.05)。治疗组和对照组的肿瘤浸润淋巴细胞(TIL)反应阳性率分别为75.0%和90.0%,差异有统计学意义(P<0.05)。随访12个月,治疗组与对照组的生存率分别为95.0%和75.0%,差异有统计学意义(P<0.05)。结论晚期可切除直肠癌术后同步放化疗的应用安全性好,可通过恢复机体的局部免疫功能来提高生存率,值得推广应用。
Objective To investigate the effect of concurrent chemoradiotherapy after advanced resectable rectal cancer surgery. Methods 80 cases of patients with advanced rectal cancer were divided into treatment group and control group according to the treatment method, 40 cases in each group. All patients underwent total mesorectal excision, postoperative treatment group patients given concurrent chemoradiation. Results There was no significant difference in the incidence of incision infection, anastomotic leakage and intestinal obstruction between the two groups (P> 0.05). The two groups of patients with adverse reactions mainly fatigue, nausea and vomiting, diarrhea and thrombocytopenia, the difference was not statistically significant (P> 0.05). The positive rates of tumor infiltrating lymphocytes (TILs) in treatment group and control group were 75.0% and 90.0%, respectively, with statistical significance (P <0.05). The follow-up of 12 months, the survival rate of the treatment group and the control group were 95.0% and 75.0%, the difference was statistically significant (P <0.05). Conclusions The application of concurrent chemoradiotherapy after advanced resectable rectal cancer is safe and can improve the survival rate by restoring the local immune function, which is worth popularizing and applying.